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Neonatal care has progressed tremendously leading to increasing number of survivors among very low birth weight (VLBW) neonates. Neonates, especially 
premature infants, are well known to have impaired innate 
immunity making them susceptible to systemic infection and 
fungal colonization [1,2]. The incidence of systemic fungal 
infection in preterm infants is reported to vary widely between 
2% and 22% [3-9]. Specifically, invasive fungal infection is 
associated with end-organ involvement in 22-34% [10,11].
Blood culture remains the gold standard for diagnosing 
fungal infection. Approximately 90% of fungal infections 
in VLBW neonates are caused by Candida species [12], and 
most of them are caused by Candida albicans and Candida 
parapsilosis with increasing recognition of infection by 
Candida tropicalis [13,14]. The risk factors associated with 
invasive candidal infection (ICI) are extreme prematurity, 
broad-spectrum antibiotic use, prolonged antibiotic therapy 
for more than 7 days, central catheter use, ventilation, vaginal 
delivery, use of H2 blockers and steroids, and abdominal 
surgery [4,15-19].
As ICI is associated with high mortality and morbidity, 
prophylactic systemic antifungal therapy has been advocated, 
especially in units with a high incidence of ICI [5]. Studies 
on incidence of ICI in India being sparse, it was felt that 
investigating the incidence of ICI would help to define protocol 
on starting prophylactic systemic antifungal therapy and also to 
implement quality improvement initiatives to reduce neonatal 
fungal infections. Although candidal species are sensitive to 
amphotericin B and azoles, there are concerns on the emergence 
of resistant organism. Knowing antifungal susceptibility pattern 
would help physicians to decide on starting empirical antifungal 
therapy.
The present study was conducted to find out the incidence 
of ICI among VLBW infants. Further, the study identified the 
mortality rate and clinical spectrum of VLBW infants with ICI 
observed over a period of 5-year.
ABSTRACT
Background: Fungal infection is one of the important causes of bloodstream infection in very low birth weight (VLBW) and 
extremely low birth weight (ELBW) infants. Objective: To find out the incidence, mortality rate, and clinical spectrum of infants 
with invasive candidal infection (ICI) among VLBW infants. Materials and Methods: A retrospective descriptive study was 
conducted over a period of 5-year at a tertiary care hospital. VLBW infants admitted within 24 h of birth were included. The clinical 
characteristics and the outcome of the infants who developed fungal infection were studied. The end point was either discharge from 
the unit or death of the infants who developed fungal sepsis. Results: During the study period, there were a total of 641 VLBW 
infants admitted and 18 neonates had invasive fungal infections (ICI), which accounted to an incidence of 2.8%. The mean birth 
weight was 1010±289 g, and the mean gestational age (GA) was 28.6±2.93 weeks. End organ involvement was found in 9 (50%) 
infants with the eye being the most commonly involved organ (39%) followed by renal involvement (22%). Stratified analysis 
revealed that lower GA and lower birth weight were associated with higher incidence of ICI (p<0.01). Out of 18 isolates that were 
identified, Candida albicans was the most common organism isolated in 13 (72%) infants. More than ¼ of the cultures (28%) 
isolated were non-albicans Candida species. The mortality rate among infants with ICI was 11% (2/18). The two infants who died 
had septicemia caused by C. albicans and multiple (renal and eye) end organ involvement. All-cause mortality in the study group 
was also 11% (73/641). Conclusion: The incidence of ICI without systemic antifungal prophylaxis was 2.8% and 5.3% in VLBW 
and ELBW infants, respectively. C. albicans was more common, but the emergence of Candida non-albicans is seen as a growing 
threat with some of them displaying resistance to azole group of antifungals.
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MATERIALS AND METHODS
A retrospective descriptive study was conducted among VLBW 
infants admitted to Neonatal Intensive Care Unit (NICU) of 
a tertiary care hospital, between January 2010 and December 
2014. The neonatal unit is a 60 bedded level III-B accredited unit 
with 24 intensive care beds. It has an average annual admission 
of 1100 neonates. Institutional Ethical Approval (IEC-NI/16/
APR/52/23) was obtained for conducting the study.
Neonates with birth weight <1500 g (VLBW) admitted within 
24 h of birth were included. The clinical characteristics and the 
outcome of the infants who developed fungal infection were 
studied. The end point was either discharge from the unit or death of 
the infants who developed fungal sepsis. Data were retrieved from 
the medical records department using inpatient database classified 
according to the International Code of Diseases (ICD) 10. The 
codes used were ICD code “P 07.3” (for preterm) and ICD code 
“P 37.5” (neonatal candidiasis). Neonatal admission records were 
also verified. The data were cross-checked with laboratory registry 
of the microbiology department. The following clinical parameters 
were collected: Gestational age (GA), birth weight, sex, mode of 
delivery, intramural delivery or outborn, ventilation, the length of 
stay, the day of occurrence of ICI, end organ involvement, and the 
outcome. Data were stratified into groups based on birth weight 
(<800 g, 800-1000 g, and 1001-1499 g) and GA (<26 weeks, 
26-28 weeks, and >28 weeks) of the infants.
We defined the presence of ICI if Candida was isolated from 
sterile site (blood, cerebrospinal fluid [CSF], or urine) in the 
presence of systemic signs of infection. The day of obtaining 
positive blood culture was considered as day of acquiring the 
candidal infection. Species identification was made, and its 
antifungal susceptibility pattern was documented. End organ 
involvement was considered when there was any evidence of 
organ involvement following ICI.
During the study period, the unit protocol in the management 
of VLBW infants was as follows: All VLBW infants were started 
on total parenteral nutrition (TPN) with minimal enteral feed 
started within 24 h of birth with expressed breast milk. The feed 
was increased by 10-20 ml/kg/day until a target feeding volume 
of 150 ml/kg/day was achieved. To administer TPN, all the infants 
were started on central line (umbilical venous line or peripherally 
inserted central cannula) within 24 h of birth. All infants received 
2 drops of clotrimazole swabbed over oral cavity while either 
on orogastric feeds or on antibiotics. Prophylactic systemic 
fluconazole was not used during the study period. Piperacillin 
with tazobactam and amikacin were used for late onset bacterial 
sepsis, and antibiotics were changed depending on the sensitivity 
and clinical response.
Infants with suspected sepsis underwent septic workup 
including blood culture, total blood count, differential count, 
absolute neutrophil count, and quantitative C-reactive protein 
(CRP). 1 ml of blood was obtained by venipuncture from a 
peripheral vein under aseptic precautions and was inoculated into 
Bactec Pediatric blood culture vial. Blood culture was considered 
sterile if there was no growth detected after 7 days of incubation. If 
the blood culture grew fungus or when clinician suspected fungal 
sepsis, amphotericin B was started. Urine culture was obtained 
by suprapubic aspiration done under aseptic precautions before 
starting on amphotericin B. The infants were screened for end 
organ involvement within 72 h following isolation of Candida 
from the blood stream. Criteria for end organ involvement were as 
follows: CNS infection-if there was CSF pleocytosis or isolation 
of Candida from CSF or cranial ultrasound showing cerebral 
abscess, eye infection in presence of chorioretinitis as opined 
by ophthalmologist, cardiac infection in presence of vegetation 
detected by two-dimensional echocardiography; hepatic and/or 
renal infection-if ultrasonography showed evidence of fungal 
balls or abscess. Either voriconazole or flucytosine was added if 
there had been evidence of eye or CNS involvement, respectively. 
Blood culture was repeated every 48 h till culture became sterile.
Blood culture vials were incubated for 5 days in a continuous 
monitoring blood culture system, the Bactec 9120 (BD, USA), 
in the Department of Microbiology. Urine or CSF samples were 
inoculated into cystine lactose electrolyte deficient agar/blood 
agar/MacConkey agar. Once the candidal growth is identified, 
the samples were further processed using VITEK 2 Compact 
(bioMerieux, France) for species identification and susceptibility 
pattern.
Statistical Analysis
Continuous variables were expressed in mean and standard 
deviation for normal distribution and median and interquartile 
range for non-normal distribution. Categorical variables were 
expressed as number and percentage. Categorical variables were 
analyzed using Chi-square test. All the analyses were done using 
SPSS version 18.0 software.
RESULTS
During the study period, there were a total of 641 VLBW infants 
admitted to the NICU. Of them, 18 neonates had ICI, which 
accounted to an incidence of 2.8%. Baseline characteristics 
are depicted in Table 1. None of the infants had early onset 
(<72 h of life) ICI. All the infants who developed ICI had prior 
use of antibiotics. Mean antibiotic duration before ICI was 
12.3±5.2 days. 11% of infants received antibiotics for <7 days. 
Half of the infants had prior bacterial sepsis. None of the infants 
received H2 blockers. Candidal growth was reported as early as 
2 days and latest by 5 days of sending blood cultures in all infants 
with fungal infection. After initiation of antifungal therapy, in 
the majority of infants (77%), fungal clearance occurred within 
4 days.
End organ involvement was found in 9 (50%) infants. Eye 
and renal involvement was detected in 7 (39%) and 4 (22%), 
respectively. One infant had a hepatic granuloma. None of the 
infants with ICI had infective endocarditis, candidal meningitis, 
or cerebral abscess.
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The incidence of ICI is depicted in the Fig. 1 and Table 2. 
Incidence of ICI among extremely low birth weight (ELBW) 
and VLBW infants were 5.3% (10/187) and 2.8% (18/641), 
respectively. Stratified analysis revealed that lower GA and lower 
birth weight were associated with higher incidence of ICI (p<0.01).
The hematological parameters are depicted in Table 3. 
None of the infants with ICI had absolute neutrophil count 
<1700 cells/mm3. 15 out of 18 (83%) had a positive qualitative 
CRP. Two-third of infants (12/18) had thrombocytopenia. 
Among the infants with thrombocytopenia, 9 (75%) had platelet 
count of <100,000 cells/mm3, and 4 (33%) had platelet count 
<50,000 cells/mm3 (severe thrombocytopenia).
Out of the total 18 isolates, C. albicans was the most common 
organism isolated in 13 (72%) infants followed by C. tropicalis 
in 4 (22%) and C. parapsilosis in 1 (5%) (Fig. 2). More than ¼ 
of cultures (28%) isolated were non-albicans Candida species. 
All the C. albicans were sensitive to azoles whereas out of the 
5 non-albicans Candida species, 2 were resistant to fluconazole, 
itraconazole, ketoconazole, and voriconazole. Both albicans and 
non-albicans were sensitive to amphotericin B.
The mortality rate among infants with ICI was 11% (2/18). 
The two infants who died had septicemia caused by C. albicans 
and multiple (renal and eye) end organ involvement. In addition, 
the infants had bacterial sepsis before the development of fungal 
infection and received broad-spectrum antibiotics. All-cause 
mortality in the study group was also 11% (73/641).
DISCUSSION
Candida species is the third most common organism causing 
nosocomial sepsis in neonates [5]. The incidence of ICI among 
VLBW infants was 2.8% in the present study. Incidence reported 
in previous studies widely varies depending on the unit ranging 
from 2% to 12% [6,7,8,20]. Studies on incidence in developing 
countries are sparse. In a study by Singh et al., from India, 
invasive candidiasis occurred in 22.8% of preterm infants who 
stayed in NICU for more than 7 days [9].
The incidence of ICI in ELBW infants in our study was 5.3% 
when compared to the reported incidence of 5-16% [4,6,7,20]. 
The observed low incidence could be attributed to the use of 
prophylactic topical antifungal therapy in the unit, avoidance of 
use of cephalosporin group of antibiotics, and avoidance of the 
use of H2 blockers. The incidence was inversely proportional to 
the birth weight. In the present study, ICI in infants <800 g and in 
infants between 800 and 1000 g, occurred 2.5 times and 1.5 times 
more frequently, compared to VLBW infants, respectively. There Table 1: Baseline characteristics
General characteristics N (%) (n=18)
Birth weight (g) 1010±289 g*
Gestational Age (weeks) 28.6±2.93*
Male 12 (67)
Vaginal delivery (n%) 12 (67)
Outborn (n, %) 5 (28)
ICU stay before ICI (in days) 17.5 (13, 38.25)#
Mechanical ventilation 10 (56)
*Mean (±SD), #Median and interquartile range. All percentage rounded to whole 
number. ICU: Intensive care unit, ICI: Invasive candidal infection, GA: Gestational 
age










≤800 g 5 70 7.14 0.009
801-1000 g 5 117 4.27
1001-1500 g 8 454 1.76
<26 wks 5 53 7.54 0.023
26-28 wks 3 142 2.11
>28 wks 10 446 2.24
*Using Chi-square test. ICI: Invasive candidal infection, GA: Gestational age
Figure 1: Incidence of invasive candidal infection (%) according to 







Figure 2: Distribution of organism
Table 3: Hematological parameters
Hematological variables Median (IQR)
Hemoglobin (g%) 9 (10-11)
Total count (cells/mm3) 13550 (10847-18040)
ANC (cells/mm3) 6940 (5521-10231)
Quantitative CRP (mg/dL) 2 (1.32-4.2)
Platelet count (cells/mm3) 1.01 (0.6-3.26)
IQR: Interquartile range, ANC: Absolute neutrophil count
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was a significant increased incidence of ICI in lower birth weight 
(p=0.023). Peak incidence was observed in infants <26 weeks after 
which the incidence plateaued. There was a significant increased 
incidence of ICI in lower GA (p<0.01). Previous studies have also 
shown strong inverse relationship for both GA and birth weight 
with ICI [4,6,21,22]. Nearly, 90% of infants received antibiotics 
for more than 7 days. Among infants with ICI, two-third were 
born by vaginal delivery and two-third were male infants, both of 
which have been described as known risk factors for developing 
fungal infection [17].
In the present study, the median day of onset of ICI was 
17.5 days ranging from 9 to 95 days. The review of the literature 
shows a predominant occurrence of systemic candidiasis between 
2nd and 4th week of life [17,11] with longer duration of stay 
contributing to the development of fungal sepsis.
Quantitative CRP (cutoff of 1 mg/dL) was positive in 83% of 
infants with fungal infection. Absolute neutrophil count and total 
white cell count were not contributory. We observed that two-
third of the infants with ICI had thrombocytopenia with only 22% 
showing severe thrombocytopenia (count <50,000/mm3). Severe 
thrombocytopenia has been reported to be one of the predictive 
markers for the diagnosis of candidemia [21].
As clinical presentations and markers of infection are non-
specific, the diagnosis of ICI was predominantly based on the 
culture positivity. In the present study, culture reports were 
obtained in 48 h, but none of them had positive fungal culture 
after 5 days of sending blood culture. This will help the treating 
physician to stop empirical antifungal therapy in 5 days if culture 
is sterile.
ICI has been associated with end organ involvement in 22-34% 
in various studies [10,11]. We observed end organ involvement 
secondary to dissemination in 50% of the cases. In our study, both 
the infants who died were ELBW infants, with GA of <28 weeks; 
had prior bacterial infection; were on broad-spectrum antibiotics 
at the time of fungal sepsis; had candiduria, multiple end organ 
involvement, and C. albicans infection susceptible to amphotericin 
B. We could not study the risk factors associated with mortality as 
the sample size was small. The study recommends that all infants 
developing ICI should be screened for end organ involvement for 
assessing the severity of the infection. This would also help to 
decide the duration of treatment and to prognosticate. Mortality 
rate among infants with ICI in our center was in the lower limit of 
the reported mortality rate, which ranged from 11% to 30% in the 
literature [7,10,17,18,23-25].
The predominant organism isolated was C. albicans (72%), 
which is in agreement with previous studies [7,17,20]. In our 
study, more than 25% of the total fungal isolates were non-albicans 
Candida species, which is in concordance with various published 
reports [16,26]. However, in a study by Chaurasia et al., non-
albicans Candida species were isolated in 80% of the neonates 
studied [14]. In our study, out of 5 non-albicans Candida species, 
2 were resistant to fluconazole, itraconazole, ketoconazole, 
and voriconazole. Hence, emergence of non-albicans Candida 
species has been a threat to neonatal units [27,28]. This makes it 
imperative to find both the species and antifungal susceptibility 
for all the fungal isolates. In our unit, amphotericin B should 
remain as drug of choice with the emergence of non-albicans, as 
all the isolates were susceptible to amphotericin B.
Evidence from a meta-analysis of 10 clinical trials involving 
1371 infants has shown a significant reduction in the incidence 
of ICI among infants on fluconazole prophylaxis [19]. Red book 
of infectious diseases (2012) recommends the use of fluconazole 
prophylaxis in institutes with 5-10% of fungal infection incidence 
among ELBW infants [29]. Before implementation of fluconazole 
prophylaxis, individual units should have their own data on the 
incidence of fungal infection. The ICI incidence rate of 5.7%, 
observed in the current study, has helped us to plan on starting 
fluconazole prophylaxis for ELBW infants. It also substantiates 
the importance of epidemiological data to implement appropriate 
preventive and therapeutic strategies in all neonatal units and 
thereby decreasing morbidity and mortality.
CONCLUSION
The incidence of ICI without systemic antifungal prophylaxis 
was 2.8% and 5.3% in VLBW and ELBW infants, respectively. 
Incidence increases significantly with decreasing GA and birth 
weight. C. albicans were more common, but the emergence of 
Candida non-albicans is seen as a growing threat with some 
of them displaying resistance to azoles group of antifungals. 
Epidemiological data such as incidence of fungal sepsis are 
important to implement appropriate preventive and therapeutic 
strategies in all neonatal units.
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